Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: A preliminary report.
Antibodies
COVID-19
Humoral immunity
T2DM
Journal
Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250
Informations de publication
Date de publication:
Historique:
received:
15
12
2020
revised:
18
12
2020
accepted:
20
12
2020
pubmed:
2
1
2021
medline:
12
3
2021
entrez:
1
1
2021
Statut:
ppublish
Résumé
Patients with diabetes mellitus (DM) often demonstrate impaired antibody response to influenza/hepatitis B vaccines. Hence, we compared anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with and without type 2 diabetes mellitus (T2DM). Records of non-severe COVID-19 patients admitted at our institution between April 10, 2020 and May 20, 2020 were retrieved. Qualitative detection of total (IgG + IgM) anti-SARS-CoV-2 antibody was performed using electrochemiluminescence immunoassay in plasma samples collected at least 14 days post-polymerase chain reaction (PCR) confirmation of diagnosis. Thirty-one non-severe COVID-19 patients were included. Nine patients (29%) had T2DM with mean HbA COVID-19 patients with T2DM may not undergo seroconversion even after two weeks of diagnosis. Impaired seroconversion could theoretically increase the risk of reinfections in patients with DM. However, the finding requires validation in large-scale studies involving serial estimations of anti-SARS-CoV-2 antibodies in patients with and without DM.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Patients with diabetes mellitus (DM) often demonstrate impaired antibody response to influenza/hepatitis B vaccines. Hence, we compared anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with and without type 2 diabetes mellitus (T2DM).
METHODS
METHODS
Records of non-severe COVID-19 patients admitted at our institution between April 10, 2020 and May 20, 2020 were retrieved. Qualitative detection of total (IgG + IgM) anti-SARS-CoV-2 antibody was performed using electrochemiluminescence immunoassay in plasma samples collected at least 14 days post-polymerase chain reaction (PCR) confirmation of diagnosis.
RESULTS
RESULTS
Thirty-one non-severe COVID-19 patients were included. Nine patients (29%) had T2DM with mean HbA
CONCLUSIONS
CONCLUSIONS
COVID-19 patients with T2DM may not undergo seroconversion even after two weeks of diagnosis. Impaired seroconversion could theoretically increase the risk of reinfections in patients with DM. However, the finding requires validation in large-scale studies involving serial estimations of anti-SARS-CoV-2 antibodies in patients with and without DM.
Identifiants
pubmed: 33385765
pii: S1871-4021(20)30530-0
doi: 10.1016/j.dsx.2020.12.035
pmc: PMC7762626
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
193-196Informations de copyright
Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no conflicts of interest.
Références
Clin Exp Immunol. 2013 Oct;174(1):129-38
pubmed: 23731267
Science. 2020 Aug 14;369(6505):818-823
pubmed: 32616673
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
Lancet. 2020 May 16;395(10236):1527-1529
pubmed: 32353328
Front Immunol. 2020 Jul 03;11:1662
pubmed: 32719687
Diabetes Res Clin Pract. 2020 Apr;162:108132
pubmed: 32234504
Lancet Infect Dis. 2021 Jan;21(1):3-5
pubmed: 33058796
J Infect. 2020 Nov;81(5):816-846
pubmed: 32619697
Diabetes Res Clin Pract. 2016 May;115:76-82
pubmed: 27242126
Emerg Microbes Infect. 2020 Dec;9(1):940-948
pubmed: 32357808
Transl Res. 2014 Jan;163(1):53-63
pubmed: 23927943
J Am Geriatr Soc. 2020 Oct;68(10):2179-2183
pubmed: 32638347
Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-792
pubmed: 32687793
Diabetes Res Clin Pract. 2020 Aug;166:108300
pubmed: 32663490
Arch Dis Child. 1998 Jan;78(1):54-7
pubmed: 9534677
FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):259-65
pubmed: 10575137
Diabete Metab. 1992 May-Jun;18(3):187-201
pubmed: 1397473
Mol Metab. 2020 Sep;39:101044
pubmed: 32585364
J Infect. 2020 Aug;81(2):e72-e73
pubmed: 32389787
Prim Care Diabetes. 2021 Feb;15(1):18-20
pubmed: 32800450
Clin Microbiol Infect. 2021 Mar;27(3):315-318
pubmed: 33285276
BMC Infect Dis. 2020 Jun 19;20(1):429
pubmed: 32560694
Diabetes Care. 2000 Jan;23(1):95-108
pubmed: 10857977